利用现代多维联用色谱技术,研究不同配伍情况下茵陈蒿汤口服后体内成分及其动态变化规律,阐明茵陈蒿汤有效成分的体内命运,阐释了该方药物代谢层面的配伍意义;同时利用代谢组学对整体代谢轮廓的描述,评价复杂性多元(方剂成分及代谢产物...利用现代多维联用色谱技术,研究不同配伍情况下茵陈蒿汤口服后体内成分及其动态变化规律,阐明茵陈蒿汤有效成分的体内命运,阐释了该方药物代谢层面的配伍意义;同时利用代谢组学对整体代谢轮廓的描述,评价复杂性多元(方剂成分及代谢产物)输入的调整带来整体效应的变化,最大限度从对证侯的整体效应变化层面揭示配伍意义。在此基础上,提出了中医方剂药物代谢组学(pharmacometabolomics of chinmediformulae)的概念。展开更多
OBJECTIVE To investigate gene mutations of epidermal growth factor receptor （EGFR） and K-RAS （Kirsten rat sarcoma viral oncogene） in Chinese patients with non-small cell lung cancer （NSCLC）, and study the correl...OBJECTIVE To investigate gene mutations of epidermal growth factor receptor （EGFR） and K-RAS （Kirsten rat sarcoma viral oncogene） in Chinese patients with non-small cell lung cancer （NSCLC）, and study the correlation with its protein expression and its clinical significance on gefitinib.METHODS Detect the EGFR and K-RAS gene mutations status by gene sequencing and use the method of immunohistochemistry to detect EGFR and K-RAS protein expression.RESULTS The frequency of EGFR mutations was 33%, mainly located in exon 19 and exon 21. The frequency of K-RAS mutations was 5.5%, mainly located in codon 12. There was no case which both had EGFR and K-RAS mutations, suggesting a mutually exclusive relationship between the two. EGFR mutations are more common in adenocarcinomas （particularly those with bronchioloalveolar features）, nonsmokers and females. 16% were detected EGFR positive expression and had no correlation with EGFR mutation （P 〉 0.05）, but had significant correlation with mutation in exon 19 （P 〈 0.05）. The frequency of K-RAS positive expression was 52.5% and had no correlation with K-RAS mutation （P 〉 0.05）. Twelve （8 cases were protein-negative） out of 15 gefitinib-treated NSCLC patients with disease control carry EGFR mutations.CONCLUSION EGFR protein expression has some correlation with exon 19 mutations. Combined detection of EGFR and K-RAS gene mutations can help clinicians to choose patients who may benefit from EGFR tyrosine kinase inhibitor （EGFR-TKI） and to predict the response and prognosis of gefitinib.展开更多
文摘利用现代多维联用色谱技术,研究不同配伍情况下茵陈蒿汤口服后体内成分及其动态变化规律,阐明茵陈蒿汤有效成分的体内命运,阐释了该方药物代谢层面的配伍意义;同时利用代谢组学对整体代谢轮廓的描述,评价复杂性多元(方剂成分及代谢产物)输入的调整带来整体效应的变化,最大限度从对证侯的整体效应变化层面揭示配伍意义。在此基础上,提出了中医方剂药物代谢组学(pharmacometabolomics of chinmediformulae)的概念。
文摘OBJECTIVE To investigate gene mutations of epidermal growth factor receptor （EGFR） and K-RAS （Kirsten rat sarcoma viral oncogene） in Chinese patients with non-small cell lung cancer （NSCLC）, and study the correlation with its protein expression and its clinical significance on gefitinib.METHODS Detect the EGFR and K-RAS gene mutations status by gene sequencing and use the method of immunohistochemistry to detect EGFR and K-RAS protein expression.RESULTS The frequency of EGFR mutations was 33%, mainly located in exon 19 and exon 21. The frequency of K-RAS mutations was 5.5%, mainly located in codon 12. There was no case which both had EGFR and K-RAS mutations, suggesting a mutually exclusive relationship between the two. EGFR mutations are more common in adenocarcinomas （particularly those with bronchioloalveolar features）, nonsmokers and females. 16% were detected EGFR positive expression and had no correlation with EGFR mutation （P 〉 0.05）, but had significant correlation with mutation in exon 19 （P 〈 0.05）. The frequency of K-RAS positive expression was 52.5% and had no correlation with K-RAS mutation （P 〉 0.05）. Twelve （8 cases were protein-negative） out of 15 gefitinib-treated NSCLC patients with disease control carry EGFR mutations.CONCLUSION EGFR protein expression has some correlation with exon 19 mutations. Combined detection of EGFR and K-RAS gene mutations can help clinicians to choose patients who may benefit from EGFR tyrosine kinase inhibitor （EGFR-TKI） and to predict the response and prognosis of gefitinib.
